Skip to main content
Clinical Trials/NCT04863092
NCT04863092
Completed
N/A

Intervention to Educate and Improve Underrepresented Populations' Participation in Clinical Trials

University of Colorado, Denver1 site in 1 country188 target enrollmentNovember 24, 2020
ConditionsCancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cancer
Sponsor
University of Colorado, Denver
Enrollment
188
Locations
1
Primary Endpoint
Change in knowledge and understanding of and intent to participate in Clinical Trials (CTs)
Status
Completed
Last Updated
11 months ago

Overview

Brief Summary

This proposal aims to leverage ongoing community outreach efforts and the Cancer Center's aims to improve recruitment to clinical trials by educating the catchment and making referrals to engage current UCCC patients not taking advantage of available CTs at this institution and affiliated hospitals. The Cancer Prevention and Control Program within UCCC works to develop and evaluate novel approaches to primary prevention, disseminate preventative interventions in population-based settings, and to improve health services delivery and outcomes for cancer patients and survivors. A primary emphasis is placed on those from underrepresented populations, including Hispanics, residents of outlying rural areas, and those in areas of poverty. Efforts to meet the Cancer Center's priorities include interventions to promote awareness and recruitment of eligible patients to available CTs in the catchment area (the state of Colorado).

Detailed Description

Clinical Trial Education Intervention: The educational intervention will be delivered to approximately 200 participants by the Community Health Educators (CHEs) who will conduct workshops to deliver content and educational materials to patients about the importance of participating in cancer clinical trials. The workshops will last approximately 60 minutes, with 20 minutes to educate participants and 10 minutes to discuss the materials and answer any questions. Prior to and after the presentation, the CHE will administer the pre- and post-intervention survey to participants. Group sizes will be capped to 25 individuals per group. Additionally, the CHE and/or Patient Navigators (PNs) will set up pathways for communication with key personnel (i.e. nurse navigators, clinical research coordinators, investigators) from partnering hospitals and clinics to facilitate patient referrals and evaluation for eligibility for clinical trials. The CHE and/or PN will keep track of those individuals that are referred by the partner hospital and clinics to track if the PN referral resulted in enrollment and participation in a clinical trial. The CHE and/or PN will also record and report quarterly the number of: (a) persons referred to therapeutic/intervention CTs at the UCCC and partnering hospitals; (b) referred persons screened for therapeutic/intervention CTs at the UCCC and partnering hospitals; (c)referred persons enrolled in therapeutic/ intervention CTs at the UCCC and partnering hospitals.

Registry
clinicaltrials.gov
Start Date
November 24, 2020
End Date
August 5, 2024
Last Updated
11 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Provision to sign and date the consent form.
  • Stated willingness to comply with all study procedures and be available for the duration of the study.
  • Be over 18 years old
  • English and/or Spanish Speaking

Exclusion Criteria

  • Individuals who do not meet eligibility criteria, including individuals who do not speak English or Spanish \[at the discretion of the CHE or PN upon recruitment\];
  • Decisionally-challenged adults with cognitive or personality impairment or due to intoxication (alcohol or drugs) that might interfere with their ability to consent or participate in the study \[at the discretion of the CHE or PN upon recruitment\];
  • Individuals from vulnerable populations (e.g., inmates, homeless, pregnant women, and those with auditory impairment \[at the discretion of the CHE or PN upon recruitment\].
  • Individuals under the age of 18 years.

Outcomes

Primary Outcomes

Change in knowledge and understanding of and intent to participate in Clinical Trials (CTs)

Time Frame: 36 months

Using questionnaires to measure the change in knowledge of and understanding and intent to participate in CTs

Number of patients referred, screened, and enrolled into cancer related therapeutic CTs

Time Frame: 36 months

Monitoring the number of referrals to and enrollment in CTs will help determine effectiveness of educational materials.

Secondary Outcomes

  • Change in number of underrepresented patients participating in cancer related therapeutic CTs(36 months)
  • Identify relationships between sociodemographic variables and the attitudes towards CTs(36 months)

Study Sites (1)

Loading locations...

Similar Trials